Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

LILLY NOSES INTO INSULIN DELIVERY: AGREEMENT WITH CALIFORNIA BIOTECH includes license for worldwide marketing of an intranasal insulin product based on the Mountain View, Calif. biotech firm's Nazdel drug delivery technology. In a recent press release, California Biotech announced that it had signed a "letter of intent" with Lilly to "undertake clinical development and worldwide marketing" of the Nazdel system for use with insulin. The firm indicated in its 1984 annual report that its intranasal insulin product had reached human clinicals. "The license will provide for payments by Lilly to Cal Bio which could amount to more than $10 mil. over the next four to five years contingent on product development milestones being met," California Biotech said. "The license will also provide for royalties after product introduction." "The Nazdel membrane permeation enhancer for nasal administration has already been shown to be effective in delivering insulin to diabetics, potentially bypassing the injection needle and its daily trauma," California Biotech's 1984 annual report states. "The system exhibits an additional advantage over the usual subcutaneous injection for the diabetic since it delivers insulin into the bloodstream where it can act more readily at mealtime." Carrying the brandname Nasalin, the product is "scheduled for more extended clinical trials in 1985," the annual report adds. Under the Nazdel system, "the drug to be delivered is mixed in a nasal spray that can deliver it across the mucous membrane into the circulatory system," the company noted. California Biotech said its membrane permeation enhancer for nasal administration is "currently being tested for its capability to deliver a large number of other drugs."

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts